{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Prostate+Cancer&page=23", "query": { "condition": "Metastatic Prostate Cancer", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 1273, "total_pages": 128, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Prostate+Cancer&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Prostate+Cancer&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T21:50:09.385Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05653856", "title": "Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastasis From Malignant Tumor of Prostate (Disorder)" ], "interventions": [ { "name": "64Cu-PSMA I&T", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Curium US LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 26, "start_date": "2022-12-05", "completion_date": "2023-05-17", "has_results": true, "last_update_posted_date": "2025-01-24", "last_synced_at": "2026-10-27T21:50:09.385Z", "location_count": 9, "location_summary": "New Haven, Connecticut • Hines, Illinois • Baltimore, Maryland + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Hines", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05653856" }, { "nct_id": "NCT04886986", "title": "Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "225Ac-J591", "type": "DRUG" }, { "name": "177Lu-PSMA-617", "type": "DRUG" }, { "name": "68Ga-PSMA-11", "type": "DRUG" }, { "name": "177Lu-PSMA-I&T", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "MALE", "summary": "18 Years to 99 Years · Male only" }, "enrollment_count": 42, "start_date": "2021-06-30", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-27T21:50:09.385Z", "location_count": 2, "location_summary": "Brooklyn, New York • New York, New York", "locations": [ { "city": "Brooklyn", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04886986" }, { "nct_id": "NCT04060394", "title": "Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Phase I and Phase II: LAE001/prednisone + afuresertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Laekna Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 49, "start_date": "2019-09-13", "completion_date": "2024-03-30", "has_results": false, "last_update_posted_date": "2024-10-10", "last_synced_at": "2026-10-27T21:50:09.385Z", "location_count": 12, "location_summary": "Tucson, Arizona • Encinitas, California • Norwich, Connecticut + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04060394" }, { "nct_id": "NCT03796767", "title": "Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Prostate Carcinoma", "Metastatic Malignant Neoplasm in the Bone", "Metastatic Malignant Neoplasm in the Lymph Nodes", "Oligometastasis", "Prostate Adenocarcinoma", "PSA Failure" ], "interventions": [ { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Metastasectomy", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 20, "start_date": "2019-09-09", "completion_date": "2026-03-11", "has_results": true, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-27T21:50:09.385Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03796767" }, { "nct_id": "NCT02952534", "title": "A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "Rucaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "pharmaand GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 277, "start_date": "2017-02-15", "completion_date": "2021-07-27", "has_results": true, "last_update_posted_date": "2023-06-09", "last_synced_at": "2026-10-27T21:50:09.385Z", "location_count": 58, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02952534" }, { "nct_id": "NCT06778863", "title": "A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Unresectable Solid Tumor", "Metastatic Solid Tumor", "Colorectal Adenocarcinoma", "Pancreatic Adenocarcinoma", "Lung Cancer", "Ovarian Cancer", "Breast Cancer", "Head and Neck Squamous Cell Carcinoma", "Prostate Cancer", "Bladder Cancer" ], "interventions": [ { "name": "CLSP-1025", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clasp Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2025-02-28", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-27T21:50:09.385Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 14 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06778863" }, { "nct_id": "NCT02607228", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castrate-Resistant Prostate Cancer" ], "interventions": [ { "name": "Alobresib", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 31, "start_date": "2015-12-08", "completion_date": "2019-09-03", "has_results": true, "last_update_posted_date": "2020-12-08", "last_synced_at": "2026-10-27T21:50:09.385Z", "location_count": 4, "location_summary": "San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02607228" }, { "nct_id": "NCT04634344", "title": "Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "DZD2269", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dizal Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 16, "start_date": "2021-04-12", "completion_date": "2022-05-05", "has_results": false, "last_update_posted_date": "2022-07-11", "last_synced_at": "2026-10-27T21:50:09.385Z", "location_count": 2, "location_summary": "New York, New York • Pittsburgh, Pennsylvania", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04634344" }, { "nct_id": "NCT04927663", "title": "11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Carcinoma", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8", "Solid Tumor, Adult", "Solid Tumor", "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "11C-YJH08", "type": "DRUG" }, { "name": "Optional Tumor Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Rahul Aggarwal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 2, "start_date": "2021-08-10", "completion_date": "2025-02-28", "has_results": true, "last_update_posted_date": "2025-05-20", "last_synced_at": "2026-10-27T21:50:09.385Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04927663" }, { "nct_id": "NCT05968599", "title": "A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostatic Neoplasms, Castration-Resistant" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 2731, "start_date": "2023-07-24", "completion_date": "2025-02-14", "has_results": true, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-10-27T21:50:09.385Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05968599" } ] }